29 mei 2012: TACE - Trans Arteriële Chemo Embolisatie plus RFA - Radio Frequency Ablation lijkt de beste behandeling voor primaire leverkanker

28 november 2006: Bron: 1: World J Gastroenterol. 2006 Aug 21;12(31):5060-3.

Een Chinese studie van 1126 gevallen van leverkanker bewijst dat TACE met RFA de beste combinatie behandeling is voor primaire levertumoren.

RESULTATEN: Totaal 874 patienten werden gevolgd voor een periode van 2 tot 63 maanden. De overall 1-, 3- en 5- jaars overlevingscijfers waren 67.8%, 28.7% en 18.8% respectievelijk. De 1- 3- en 5- jaars overlevingscijfers van patienten die alleen TACE kregen waren 74.7%, 41.4%, 36.9% voor hepatectomy (operatie van levertumoren) en 78.9%, 40.4%, 37.5% na hepatectomy. Het effectieve cijfer (PR + NC) na TACE en RFA was 93.4%, de 1- en 3- jaars overlevingscijfers waren 74.5% en 36.8% na TACE en RFA. Het effectieve cijfer van PR + NC na TACE was 83.2%. De 1-, 3- en 5- jaars overlevingscijfers waren 69.3%, 21.7%, 8.4% na TACE. Het effectieve cijfer van PR + NC na TAI was 27.5%, de 1- en 2- jaars overlevingscijfers waren 11.6% en 0% na TAI. De leverfunctie, color-ultrasonography finding en alpha-fetoprotein na TACE + RFA, TACE en TAI werden vergeleken. Er was geen significant verschil in iedere index afzonderlijk tussen TACE en RFA of TACE als ook in leverfunctie tussen TACE en RFA of tussen TACE en TAI

World J Gastroenterol. 2006 Aug 21;12(31):5060-3

Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer.Liu YM, Qin H, Wang CB, Fang XH, Ma QY.
Department of Interventional Medicine, First Hospital, Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. super2000haohao@163.com

AIM: To verify the effect of combined interventional therapy for hepatocellular carcinoma (HCC).

METHODS: The clinical data of 1126 HCC patients who received combined interventional therapy for transcatheter arterial chemoembolization (TACE) before or after hepatectomy, TACE and radio-frequency ablation (RFA), Chinese medicine treatment and biotherapy after TACE or transcatheter arterial infusion (TAI), were reviewed according to the results of their liver function, alpha-fetoprotein, image data, color-ultrasonography finding and survival rate.

RESULTS: A total of 874 patients were followed up for a period of 2 to 63 mo. The overall 1-, 3- and 5- year survival rates were 67.8%, 28.7% and 18.8% respectively. The 1- 3- and 5- year survival rates of patients who received TACE were 74.7%, 41.4%, 36.9% before hepatectomy and 78.9%, 40.4%, 37.5% after hepatectomy. The effective rate (PR + NC) after TACE and RFA was 93.4%, the 1- and 3- year survival rates were 74.5% and 36.8% after TACE and RFA. The effective rate of PR + NC after TACE was 83.2%. The 1-, 3- and 5- year survival rates were 69.3%, 21.7%, 8.4% after TACE. The effective rate of PR + NC after TAI was 27.5%, the 1- and 2- year survival rates were 11.6% and 0% after TAI. The liver function, color-ultrasonography finding and alpha-fetoprotein after TACE + RFA, TACE and TAI were compared. There was no significant difference in each index between TACE and RFA or TACE as well as in liver function between TACE and RFA or between TACE and TAI.

CONCLUSION: The therapeutic effectiveness of TACE before or after hepatectomy is most significant, while the effect of TACE and RFA is better than that of TACE, and the effect of TAI is minimal. PMID: 16937507 [PubMed - in process]


Plaats een reactie ...

Reageer op "Leverkanker: TACE - Trans Arteriele Chemo Embolisatie eventueel gevolgd door RFA - Radio Frequency Ablation geeft significant betere overleving en betere kwaliteit van leven na analyse van 1126 patienten met primaire leverkanker - HCC"


Gerelateerde artikelen
 

Gerelateerde artikelen

TACE met lokaal hyperthermie >> TCM in de vorm van de Fuzheng >> Arsenic trioxide intraveneus >> TACE plus gemoduleerd virus >> TACE met ATO - Arseentrioxide >> Arsenicum trioxide (ATO) geeft >> Leverkanker: Tace - Trans >> Leverkanker: TACE in combinatie >> Leverkanker: TACE - Trans >> Ethanol: TACE - Transarteriële >>